UniProt Q9V2J8
GlgA glycogen synthase (Q9V2J8)
GlgA glycogen synthase (UniProt Q9V2J8), EC 2.4.1.21: 67 experimental structures on GenesisL1, 39 ligands bound, 415 pockets. Binding sites, pockets, druggability and 3D structures in GL1X.
- UniProt
- Q9V2J8
- Protein
- GlgA glycogen synthase
- EC
- 2.4.1.21
- Experimental structures
- 67
- Predicted models
- 0
- Ligands
- 39
- Pockets
- 415 · 63 records with a druggable one
Structures
67 records of Q9V2J8 in the MolNFT archive: 67 experimental, 0 predicted.
| Entry | Title | Method | Chains | Ligands | Pockets |
|---|---|---|---|---|---|
| 2BFW | Structure of the C domain of glycogen synthase from Pyrococcus abyssi | x-ray diffraction | A | SO4 | 1 (best 0.44) |
| 2BFW | Structure of the C domain of glycogen synthase from pyrococcus abyssi | x-ray diffraction | A | SO4 | 1 (best 0.44) |
| 2BIS | Structure of glycogen synthase from Pyrococcus abyssi | x-ray diffraction | A, B, C | GLC, UDP | 12 (best 0.73) |
| 2BIS | Structure of glycogen synthase from pyrococcus abyssi | x-ray diffraction | A, B, C | GLC, UDP | 12 (best 0.73) |
| 3FRO | Crystal structure of Pyrococcus abyssi glycogen synthase with open and closed conformations | x-ray diffraction | A, B, C | PO4, NHF | 14 (best 0.81) |
| 3FRO | Crystal structure of pyrococcus abyssi glycogen synthase with open and closed conformations | x-ray diffraction | A, B, C | PO4, NHF | 14 (best 0.81) |
| 3L01 | Crystal structure of monomeric glycogen synthase from Pyrococcus abyssi | x-ray diffraction | A, B | GLC, K, CL | 5 (best 0.74) |
| 3L01 | Crystal structure of monomeric glycogen synthase from pyrococcus abyssi | x-ray diffraction | A, B | GLC, K, CL | 5 (best 0.74) |
| 4S0V | Crystal structure of the human OX2 orexin receptor bound to the insomnia drug Suvorexant | x-ray diffraction | A | SUV, OLA | 5 (best 0.83) |
| 4S0V | Crystal structure of the human OX2 orexin receptor bound to the insomnia drug suvorexant | x-ray diffraction | A | SUV, OLA | 5 (best 0.83) |
| 4ZJ8 | Structures of the human OX1 orexin receptor bound to selective and dual antagonists | x-ray diffraction | A | SUV, OLA | 6 (best 0.80) |
| 4ZJ8 | Structures of the human OX1 orexin receptor bound to selective and dual antagonists | x-ray diffraction | A | SUV, OLA | 6 (best 0.80) |
| 4ZJC | Structures of the human OX1 orexin receptor bound to selective and dual antagonists | x-ray diffraction | A | 4OT, OLA | 5 (best 0.81) |
| 4ZJC | Structures of the human OX1 orexin receptor bound to selective and dual antagonists | x-ray diffraction | A | 4OT, OLA | 5 (best 0.81) |
| 5U09 | High-resolution crystal structure of the human CB1 cannabinoid receptor | x-ray diffraction | A | SO4, 7DY | 6 (best 0.81) |
| 5U09 | High-resolution crystal structure of the human CB1 cannabinoid receptor | x-ray diffraction | A | SO4, 7DY | 6 (best 0.81) |
| 5WQC | Crystal structure of human orexin 2 receptor bound to the selective antagonist EMPA determined by… | x-ray diffraction | A | 7MA, OLA | 4 (best 0.82) |
| 5WQC | Crystal structure of human orexin 2 receptor bound to the selective antagonist empa determined by… | x-ray diffraction | A | 7MA, OLA | 4 (best 0.82) |
| 5WS3 | Crystal structures of human orexin 2 receptor bound to the selective antagonist EMPA determined by… | x-ray diffraction | A | 7MA, OLA | 4 (best 0.82) |
| 5WS3 | Crystal structures of human orexin 2 receptor bound to the selective antagonist empa determined by… | x-ray diffraction | A | 7MA, OLA | 4 (best 0.82) |
| 6E59 | Crystal structure of the human NK1 tachykinin receptor | x-ray diffraction | A | L76 | 7 (best 0.77) |
| 6E59 | Crystal structure of the human NK1 tachykinin receptor | x-ray diffraction | A | L76 | 7 (best 0.77) |
| 6FJ3 | High resolution crystal structure of parathyroid hormone 1 receptor in complex with a peptide… | x-ray diffraction | A | NAG, FUC, OLA, CL | 8 (best 0.42) |
| 6FJ3 | High resolution crystal structure of parathyroid hormone 1 receptor in complex with a peptide… | x-ray diffraction | A | NH2, NAG, FUC, OLA, CL | 8 (best 0.42) |
| 6HLL | Crystal structure of the Neurokinin 1 receptor in complex with the small molecule antagonist… | x-ray diffraction | A | GBK | 4 (best 0.73) |
| 6HLL | Crystal structure of the neurokinin 1 receptor in complex with the small molecule antagonist… | x-ray diffraction | A | GBK | 4 (best 0.73) |
| 6HLO | Crystal structure of the Neurokinin 1 receptor in complex with the small molecule antagonist… | x-ray diffraction | A | GBQ, OLA | 5 (best 0.74) |
| 6HLO | Crystal structure of the neurokinin 1 receptor in complex with the small molecule antagonist… | x-ray diffraction | A | GBQ, OLA | 5 (best 0.74) |
| 6HLP | Crystal structure of the Neurokinin 1 receptor in complex with the small molecule antagonist… | x-ray diffraction | A | GAW, OLA | 4 (best 0.75) |
| 6HLP | Crystal structure of the neurokinin 1 receptor in complex with the small molecule antagonist… | x-ray diffraction | A | GAW, OLA | 4 (best 0.75) |
| 6KP6 | The structural study of mutation induced inactivation of Human muscarinic receptor M4 | x-ray diffraction | A | — | 6 (best 0.79) |
| 6KP6 | The structural study of mutation induced inactivation of human muscarinic receptor M4 | x-ray diffraction | A | — | 6 (best 0.79) |
| 6KQI | Structure of an allosteric modulator bound to the CB1 cannabinoid receptor | x-ray diffraction | A | 9GF, 9GL, OLA | 8 (best 0.84) |
| 6KQI | Structure of an allosteric modulator bound to the CB1 cannabinoid receptor | x-ray diffraction | A | 9GF, 9GL, OLA | 8 (best 0.84) |
| 6LFL | Crystal structure of a class A GPCR | x-ray diffraction | A | EBX | 5 (best 0.73) |
| 6LFL | Crystal structure of a class a GPCR | x-ray diffraction | A | EBX | 5 (best 0.73) |
| 6ME2 | XFEL crystal structure of human melatonin receptor MT1 in complex with ramelteon | x-ray diffraction | A | JEV, OLA | 6 (best 0.81) |
| 6ME2 | Xfel crystal structure of human melatonin receptor MT1 in complex with ramelteon | x-ray diffraction | A | JEV, OLA | 6 (best 0.81) |
| 6ME3 | XFEL crystal structure of human melatonin receptor MT1 in complex with 2-phenylmelatonin | x-ray diffraction | A | JEY, OLA | 5 (best 0.81) |
| 6ME3 | Xfel crystal structure of human melatonin receptor MT1 in complex with 2-phenylmelatonin | x-ray diffraction | A | JEY, OLA | 5 (best 0.81) |
| 6ME4 | XFEL crystal structure of human melatonin receptor MT1 in complex with 2-iodomelatonin | x-ray diffraction | A | ML2 | 7 (best 0.83) |
| 6ME4 | Xfel crystal structure of human melatonin receptor MT1 in complex with 2-iodomelatonin | x-ray diffraction | A | ML2 | 7 (best 0.83) |
| 6ME5 | XFEL crystal structure of human melatonin receptor MT1 in complex with agomelatine | x-ray diffraction | A | AWY, OLA | 6 (best 0.81) |
| 6ME5 | Xfel crystal structure of human melatonin receptor MT1 in complex with agomelatine | x-ray diffraction | A | AWY, OLA | 6 (best 0.81) |
| 6PS8 | XFEL MT1R structure by ligand exchange from agomelatine to 2-phenylmelatonin. | x-ray diffraction | A | JEY | 4 (best 0.82) |
| 6PS8 | Xfel MT1R structure by ligand exchange from agomelatine to 2- phenylmelatonin. | x-ray diffraction | A | JEY | 4 (best 0.82) |
| 6TPG | Crystal structure of the Orexin-2 receptor in complex with EMPA at 2.74 A resolution | x-ray diffraction | A | 7MA, OLA | 7 (best 0.82) |
| 6TPG | Crystal structure of the orexin-2 receptor in complex with empa at 2.74 a resolution | x-ray diffraction | A | 7MA, OLA | 7 (best 0.82) |
| 6TPJ | Crystal structure of the Orexin-2 receptor in complex with suvorexant at 2.76 A resolution | x-ray diffraction | A, B | OLA, SUV, NH4 | 13 (best 0.83) |
| 6TPJ | Crystal structure of the orexin-2 receptor in complex with suvorexant at 2.76 a resolution | x-ray diffraction | A, B | OLA, SUV, NH4 | 13 (best 0.83) |
| 6TPN | Crystal structure of the Orexin-2 receptor in complex with HTL6641 at 2.61 A resolution | x-ray diffraction | A | NU8, NO3, OLA | 7 (best 0.82) |
| 6TPN | Crystal structure of the orexin-2 receptor in complex with HTL6641 at 2.61 a resolution | x-ray diffraction | A | NU8, NO3, OLA | 7 (best 0.82) |
| 6V9S | Structure-based development of subtype-selective orexin 1 receptor antagonists | x-ray diffraction | A | JHC, CLR, OLA | 4 (best 0.82) |
| 6V9S | Structure-based development of subtype-selective orexin 1 receptor antagonists | x-ray diffraction | A | JHC, CLR, OLA | 4 (best 0.82) |
| 6W25 | Crystal structure of the Melanocortin-4 Receptor (MC4R) in complex with SHU9119 | x-ray diffraction | A | CA, OLA | 5 (best 0.60) |
| 6W25 | Crystal structure of the melanocortin-4 receptor (MC4R) in complex with SHU9119 | x-ray diffraction | A | NH2, CA, OLA | 5 (best 0.60) |
| 7BR3 | Crystal structure of the protein 1 | x-ray diffraction | A | 1QW, F5O | 5 (best 0.85) |
| 7BR3 | Crystal structure of the protein 1 | x-ray diffraction | A | 1QW, F5O | 5 (best 0.85) |
| 7FEE | Crystal structure of the allosteric modulator ZCZ011 binding to CP55940-bound cannabinoid receptor 1 | x-ray diffraction | A | CLR, 9GF, 7IC, OLA | 8 (best 0.87) |
| 7FEE | Crystal structure of protein L | x-ray diffraction | A | CLR, 9GF, 7IC, OLA | 8 (best 0.87) |
7 records more on the page itself.
Ligands
- OLA · Oleic acid · in 36 records
- 7MA · N-ethyl-2-[(6-methoxypyridin-3-yl)-(2-methylphenyl) sulfonyl-amino]-N-(pyridin-3-ylmethyl)ethanamide · in 6 records
- CLR · Cholesterol · in 6 records
- SUV · [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl) phenyl]methanone · in 6 records
- 9GF · 2-[(1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]-5-(2-methyloctan-2-yl)phenol · in 4 records
- CL · Chloride ion · in 4 records
- GLC · alpha-D-glucopyranose · in 4 records
- JEY · N-[2-(5-methoxy-2-phenyl-1H-indol-3-yl)ethyl]acetamide · in 4 records
- SO4 · Sulfate ion · in 4 records
- 7DY · N-[(2S,3S)-4-(4-chlorophenyl)-3-(3-cyanophenyl)butan-2-yl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide · in 3 records
- 1QW · (2R)-2,3-dihydroxypropyl dodecanoate · in 2 records
- 4OT · [5-(2-fluorophenyl)-2-methyl-1,3-thiazol-4-yl]{(2S)-2-[(5-phenyl-1,3,4-oxadiazol-2-yl)methyl]pyrrolidin-1-yl}methanone · in 2 records
- 7IC · 6-methyl-3-[(1S)-2-nitro-1-thiophen-2-yl-ethyl]-2-phenyl-1H-indole · in 2 records
- 9GL · 5-chloro-3-ethyl-N-{2-[4-(piperidin-1-yl)phenyl]ethyl}-1H-indole-2-carboxamide · in 2 records
- AWY · ~{N}-[2-(7-methoxynaphthalen-1-yl)ethyl]ethanamide · in 2 records
- CA · Calcium ion · in 2 records
- EBX · 4-[[3,4-bis(oxidanylidene)-2-[[(1~{R})-1-(4-propan-2-ylfuran-2-yl)propyl]amino]cyclobuten-1-yl]amino]-~{N}, ~{N}-dimethyl-3-oxidanyl-pyridine-2-carboxamide · in 2 records
- F5O · 4-[[(1R)-2-[5-(2-fluoranyl-3-methoxy-phenyl)-3-[[2-fluoranyl-6-(trifluoromethyl)phenyl]methyl]-4-methyl-2,6-bis(oxidanylidene)pyrimidin-1-yl]-1-phenyl-ethyl]amino]butanoic acid · in 2 records
- FUC · alpha-L-fucopyranose · in 2 records
- GAW · 2-[3,5-bis(trifluoromethyl)phenyl]-~{N},2-dimethyl-~{N}-[4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl) pyridin-3-yl]propanamide · in 2 records
- GBK · (2~{S},3~{S})-~{N}-[(2-methoxyphenyl)methyl]-2-phenyl-piperidin-3-amine · in 2 records
- GBQ · 5-[[(2~{R},3~{S})-2-[(1~{R})-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl) morpholin-4-yl]methyl]-1,2-dihydro-1,2,4-triazol-3-one · in 2 records
- JEV · N-{2-[(8S)-1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl]ethyl}propanamide · in 2 records
- JHC · [(2S)-2-[(2S)-butan-2-yl]-4-(5-chloro-1,3-benzoxazol-2-yl)-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone · in 2 records
- K · Potassium ion · in 2 records
- L76 · 1-(4-{[(2R,3S)-2-{(1R)-1-[3,5-bis(trifluoromethyl) phenyl]ethoxy}-3-(4-fluorophenyl)morpholin-4-yl]methyl}-1H-1,2,3-triazol-5-yl)-N,N-dimethylmethanamine · in 2 records
- ML2 · N-[2-(2-iodo-5-methoxy-1H-indol-3-yl)ethyl]acetamide · in 2 records
- NAG · 2-acetamido-2-deoxy-beta-D-glucopyranose · in 2 records
- NH2 · Amino group · in 2 records
- NH4 · Ammonium ion · in 2 records
Experiment against prediction
- 8JHQ chain A against the predicted model Q8IVW8: TM-score 0.96, RMSD 1.72 Å
- 6ME2 chain A against the predicted model P48039: TM-score 0.59, RMSD 2.16 Å
- 6ME2 chain A against the predicted model P48039: TM-score 0.59, RMSD 2.16 Å
- 6ME5 chain A against the predicted model P48039: TM-score 0.59, RMSD 2.05 Å
- 6ME5 chain A against the predicted model P48039: TM-score 0.59, RMSD 2.05 Å
- 6PS8 chain A against the predicted model P48039: TM-score 0.59, RMSD 2.11 Å
- 6PS8 chain A against the predicted model P48039: TM-score 0.59, RMSD 2.11 Å
- 6ME4 chain A against the predicted model P48039: TM-score 0.59, RMSD 2.08 Å
- 6ME4 chain A against the predicted model P48039: TM-score 0.59, RMSD 2.08 Å
- 6ME3 chain A against the predicted model P48039: TM-score 0.59, RMSD 1.89 Å
Elsewhere
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.